On 24 January 2013, orphan designation (EU/3/12/1093) was granted by the European Commission to Idis Ltd, United Kingdom, for 1,2:5,6-dianhydrogalactitol for the treatment of glioma.
The sponsorship was transferred to Regulis Consulting Europe Limited, Ireland, in April 2019.
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;